AMaRC 19-02 - BelaCarD - Phase I/II - Study of combination belantamab maf, carfilzomib, Dex RRMM
- Recruiting
- Dec 1, 2020
- 1 min read
Updated: Jan 27, 2024
BelaCarD Study
AMaRC: (PHASE I/II)
BELACARD FOR RELAPSED REFRACTORY MULTIPLE MYELOMA
A phase I/II single arm study on the efficacy of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma
AMaRC 19-02 - STUDY TITLE: A phase I/II single arm study of combination belantamab mafodotin, carfilzomib and dexamethasone in patients with early relapsed multiple myeloma (BelaCarD)
Australasian Myeloma Research Consortium
TIME FRAME
2020 – 2024
Trial registered on ANZCTR: Registration number - ACTRN12620000490976
A phase I/II single arm study on the efficacy of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma
Location
Australia
#IMS2022 - 19th International Myeloma Society Annual Meeting; Aug 25-27, LA California
